Estradiol transdermal patch - Antares
Alternative Names: E2 patch - Antares; Estradiol patch - AntaresLatest Information Update: 26 May 2022
Price :
$50 *
At a glance
- Originator Antares Pharma
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
- 25 Nov 2004 Discontinued - Clinical-Phase-Unknown for Menopausal syndrome in European Union (Transdermal)
- 25 Nov 2004 Discontinued - Preclinical for Menopausal syndrome in USA (Transdermal)